Table 3.
Glycyrrhizin/glycyrrhetinic acid chitosan nanoparticles for the treatment of HCC and liver-targeting: the therapeutic/theranostic effect and cell cultures used in the study are reported for each reference.
| Carrier | Payload | Effect | Cell Culture | Reference |
|---|---|---|---|---|
| Glycyrrhizin chitosan | - | liver targeting | hepatocytes | [81] |
| Glycyrrhizin chitosan | lamivudine | anti-retroviral | - | [82] |
| Glycyrrhizin chitosan | atorvastatin | reduction in hepatotoxicity | - | [83] |
| Glycyrrhetinic acid chitosan/PEG | doxorubicin | anti-cancer | H22; QGY-7703 |
[84] |
| Glycyrrhizin N-caproyl chitosan | - | liver targeting | H22; SMMC-7721 | [85] |
| Glycyrrhizin O-CM chitosan | paclitaxel | anti-cancer | SMMC-7721 | [86] |
| Glycyrrhetinic acid galactose chitosan | mouse IP-10 gene | liver targeting | - | [87] |